<div id="readability-page-1">Doximity (NYSE:DOCS - Get Free Report) was downgraded by investment analysts at Barclays from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Thursday,Zacks.com reports.<ul><li>Doximity is the Facebook and LinkedIn of the Medical Community</li></ul>Other analysts also recently issued research reports about the company. Mizuho reduced their price objective on Doximity from $34.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday. The Goldman Sachs Group decreased their price objective on Doximity from $28.00 to $24.00 and set a &#34;neutral&#34; rating on the stock in a research report on Thursday. BMO Capital Markets decreased their price objective on Doximity from $25.00 to $20.00 and set a &#34;market perform&#34; rating on the stock in a research report on Thursday. Robert W. Baird restated a &#34;neutral&#34; rating and set a $18.00 price objective (down from $40.00) on shares of Doximity in a research report on Thursday. Finally, Loop Capital set a $31.00 price objective on Doximity in a research report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $30.62.Get Our Latest Stock Report on Doximity<h2>Doximity Trading Up 5.1%</h2><ul><li>Doximity is an Overlooked Medical Ecosystem AI Play </li></ul>NYSE:DOCS opened at $18.93 on Thursday. Doximity has a 1 year low of $17.15 and a 1 year high of $76.51. The business has a 50 day moving average price of $23.94. The company has a market cap of $3.50 billion, a P/E ratio of 19.12, a price-to-earnings-growth ratio of 1.28 and a beta of 1.36. Doximity declared that its board has approved a stock repurchase program on Thursday, February 5th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued. <h2>Insider Buying and Selling at Doximity</h2><ul><li>Doximity Stock is an Interesting Healthcare Play</li></ul>In other Doximity news, Director Kira Scherer Wampler sold 9,000 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director owned 19,839 shares of the company's stock, valued at approximately $517,004.34. This trade represents a 31.21% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.77, for a total value of $59,502.93. Following the sale, the insider directly owned 89,396 shares in the company, valued at $2,303,734.92. This trade represents a 2.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,055 shares of company stock worth $456,061 in the last ninety days. Insiders own 31.30% of the company's stock. <h2>Institutional Trading of Doximity</h2>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC bought a new stake in Doximity during the 3rd quarter valued at $30,000. Whittier Trust Co. of Nevada Inc. boosted its position in Doximity by 59.5% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 480 shares of the company's stock valued at $35,000 after acquiring an additional 179 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Doximity by 99.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 796 shares of the company's stock valued at $35,000 after acquiring an additional 397 shares in the last quarter. Toth Financial Advisory Corp boosted its position in Doximity by 100.0% during the 4th quarter. Toth Financial Advisory Corp now owns 1,000 shares of the company's stock valued at $44,000 after acquiring an additional 500 shares in the last quarter. Finally, Atlantic Union Bankshares Corp boosted its position in Doximity by 136.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 616 shares of the company's stock valued at $45,000 after acquiring an additional 356 shares in the last quarter. Institutional investors own 87.19% of the company's stock. <h2>Key Doximity News</h2>Here are the key news stories impacting Doximity this week:<ul> <li>Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down</li> <li>Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care</li> <li>Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here's Why Doximity (DOCS) Looks Ripe for a Turnaround</li> <li>Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript</li> <li>Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?</li> <li>Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity NYSE: DOCS Insider Siddharth Sitaram Sells 2,309 Shares</li> </ul><h2>About Doximity</h2> (Get Free Report)Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers. The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.<h2>Read More</h2><ul><li>Five stocks we like better than Doximity</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li><li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Doximity Right Now?</h2>Before you consider Doximity, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

DOCS

HEAL

LGHT

Barclays has downgraded Doximity (NYSE:DOCS) from a 'strong-buy' to a 'hold' rating. Other analysts have also reduced their price targets, with Mizuho lowering it to $26, Goldman Sachs to $24, and BMO to $20. Doximity's stock currently has a consensus rating of 'Hold' and a target price of $30.62. The company has a market cap of $3.50 billion and recently approved a $500 million stock buyback program.

Barclays Downgrades Doximity (NYSE:DOCS) to Hold